Background: Lymphogranuloma venereum (LGV) is a sexually transmitted infection (STI) caused by Chlamydia trachomatis genotypes L 1 , L 2 and L 3 . This LGV is associated with significant morbidity and increased risk of HIV transmission. While fewer than two cases per year were reported in Quebec before 2005, LGV emerged in 2005-2006 with 69 cases, followed by a period of low incidence (2007)(2008)(2009)(2010)(2011)(2012), and subsequent re-emergence since 2013.
Introduction
Lymphogranuloma venereum (LGV) is a sexually transmitted infection (STI) caused by Chlamydia trachomatis genotypes L 1 , L 2 and L 3 (L [1] [2] [3] . It is associated with anogenital fistula, stenosis formation and lymphatic obstruction, among others (1) and increased risk of HIV transmission (1) (2) (3) . This information was rarely reported in industrialized countries until the early 2000s, but it has since been described in urban settings, mainly among men who have sex with men (MSM). Recent outbreaks occurred in Belgium, France, the Netherlands, the United Kingdom and the United States of America (2) . Over the last decade, LGV emerged in Canada, with sporadic outbreaks mainly in major urban centres (3) (4) (5) .
In Quebec, fewer than two cases per year were reported before a significant rise was noted in 2005 and 2006 with a total of 69 cases. A period of low incidence followed from 2007 to 2012, with a mean of nine cases per year. In 2013, an evolving outbreak started in Montréal.
The classical presentation of LGV is an inguinogenital disease, with an ulcer or papule at the site of inoculation and frequently a unilateral inguinal or femoral lymphadenopathy (1) . Many young patients are now presenting with proctitis or proctocolitis, often mimicking the first manifestations of inflammatory bowel disease (2) . Prevalence studies have recently found a higher proportion of asymptomatic cases, representing up to 25-27% of cases in MSM (6,7). 
SURVEILLANCE
In 2014, the Public Health Agency of Canada (PHAC) revised its recommendations to encourage LGV genotyping on positive C. trachomatis specimens among asymptomatic MSM with risk factors, regardless of sampled site; this was further updated in 2017 to focus on rectal specimens only (3) . Following expert advice from the Institut national de santé publique du Québec (INSPQ) (8) , systematic genotyping of all positive rectal specimens for C. trachomatis (regardless of symptomatology) was implemented in June 2016 (the value of this strategy will be assessed after two years). The INSPQ also provides guidelines on treatment of cases and partners (8) .
Given the growing epidemic, enhanced surveillance of LGV cases was pursued in Quebec with the goal of implementing targeted public health interventions. 
Demographic and risk factors
The majority of cases were in the 25-54 year age group (83%) and in Montréal (81%) ( Table 1) . Most patients were MSM (99%), with 3% (n=7) also having female partners. Half of the patients reported more than 10 sexual partners over the last 12 months (101/205; 49%). Almost all (96%) had a new partner and 84% had anonymous sexual partners. The proportion of cases with more than 20 sexual partners in the last year was higher in Montréal than in the rest of the province (27% vs 3%; p<0.001). Saunas and Internet (including smartphone networking applications) were two important means of meeting partners. Although not statistically significant (p=0.07), fewer patients (27%) had encounters with partners from outside the province in the last year in contrast to preceding years 
Clinical manifestations
Details about symptoms were available for 303/338 cases. The majority of patients had symptoms at the time of testing (n=237; 78%) ( Table 2 ). Encounter with out-of-province resident (n=208)
At least one 56 27 had only unspecific complaints (12/235; 5%). As shown in Figure 2 , more than one symptom could occur at the same time. Symptoms included proctitis (86%), ulcer or papule (12%) and lymphadenopathy (13%). Complaints associated with proctitis included bloody stools (69/201; 35%), anal pain (70/201; 34%) and rectal discharge (52/201; 26%).
Laboratory tests and treatment
The number of LGV genotyping tests performed on positive C. trachomatis samples (males and females, all sampling sites, regardless of symptoms) at the Laboratoire de santé publique du Québec are shown in Table 3 . Overall, 13% of C. trachomatis samples typable by multiplex PCR assay were genotypes L 1-3 . Some patients had more than one positive sample for a single episode. An important increase in the number of requests was noted in 2016 as a result of the recommendation to systematically genotype all rectal samples positive for C. trachomatis. 
Discussion
Incidence of LGV, which occurs within a core group of MSM living in an urban setting, has been increasing in Quebec over the last four years. The MSM population is characterized by a significant past history of STBBIs, especially HIV, a high number of sexual partners and frequent drug use. Our data show a high prevalence of proctitis as the presenting symptom, with very few classical inguinogenital diseases. The majority of the cases were diagnosed as L 2b genotypes, a variant isolated as far back as the 1980s in San Francisco (13) . A number of studies of LGV outbreaks across Europe reported a population of high-risk MSM similar to what we found in the current Quebec outbreak (2) . A large percentage of men are HIV and/or hepatitis C positive and very few cases, if any, are detected in heterosexual men or women. Asymptomatic cases have been detected, but the vast majority of cases present with symptoms of rectal infection (14) (15) (16) (17) (18) (19) .
The LGV rate remains relatively low in comparison with other common STIs including non-LGV C. trachomatis infections. In 2015, among males aged 15-75 years in Quebec, the annual incidence rates of infectious syphilis (17.2/100,000 person-year) and gonococcal infection (69.4/100,000 person-year) were significantly higher than those of LGV (2.6/100,000 person-year) (20) . As LGV is thought to be more often symptomatic than syphilis or gonococcal infection, it could be speculated that those who become infected are more likely to seek medical attention and get treatment, restricting transmission. For now, LGV is also confined to a smaller subgroup of MSM, while gonococcal and non-LGV C. trachomatis infections also involve the heterosexual population. However, the incidence prior to 2014 was likely underestimated given the exclusion of asymptomatic patients in previous case definitions. The higher proportion of asymptomatic cases in 2016 can also be partly explained by the systematic genotyping of all positive C. trachomatis rectal specimens, which started in June 2016 in Quebec.
The presented clinical manifestations are in line with recent literature reporting proctitis and proctocolitis as the most common presentation (2, 21) . Although systematic genotyping for LGV is currently performed in Quebec only for rectal specimens, there is some evidence suggesting that extrarectal LGV (pharyngeal and urethral infections) could be a potential contributor to the ongoing outbreak. In 2014, van Rooijen et al. (22) collected pharyngeal swabs from MSM and found that 1% were C. trachomatis positive; of these, 53% did not have concomitant anogenital infection. The implication of pharyngeal as well as urethral LGV in transmission of the epidemic strain remains unclear. Rectal infections have been shown to be far more common in various LGV prevalence studies (23) (24) (25) (26) . It is thus arguable that extrarectal screening would not be a cost-effective measure.
A significant improvement in adequate first prescribed treatment has been noted in 2016, possibly following educational efforts towards physicians (3, 8) . The province-wide genotyping of positive rectal C. trachomatis specimens implemented in 2016 could have contributed to improvements in case management by shortening diagnostic delays, from a mean of 30 days in 2014 (9) , to 12 days in 2016 (data not shown).
A specific subpopulation seems to be at greater risk of reinfection with higher rates of HIV infection, in line with potentially riskier sexual behaviours as shown in other reports (27, 28) . In an attempt to describe this specific subpopulation, Rönn et al. (12) found repeaters to be more likely to be infected by HIV and HCV, and to have a concomitant gonococcal infection compared with patients with a single episode of LGV. It remains unclear if serosorting, the strategy by which MSM have unprotected sexual encounters with seroconcordant partners, has a role to play in nurturing the present outbreak, as hypothesized for other STIs with higher incidence within this specific group (29, 30 
Strengths and limitations
This study provides recent surveillance data on LGV in Quebec with a high number of cases. Description of risk factors contributes to understanding the current outbreak and its sexual network. Limitations include the descriptive nature and lack of standardization of the questionnaires, both over time and across the different administrative regions, as well as some missing information. Data collecting forms have since been revised and medical teams contacted to allow better standardization. Information regarding HIV follow-up (i.e. treatment, viral load, CD4, etc.) were unfortunately not available.
Conclusion
The re-emergence of LGV in Quebec involves a core group of MSM with history of STIs, most being HIV-seropositive, with multiple partners and substantial drug use. Sporadic transmission outside of Montréal and relatively frequent reinfections highlight the potential for a further spread; this is of particular significance given the associated morbidity. The transmission among HIV-infected patients is of concern given the implication of unprotected sexual encounters within the LGV-affected population as well as the increased risk of HIV transmission associated with inflammation of rectal mucosa seen in LGV proctitis (1-3). Enhanced surveillance helps monitor and better describe this subgroup in order to tailor public health actions to reduce the risk of LGV transmission. A clinical tool for LGV was released in October 2017 to assist medical teams with LGV screening, diagnosis, treatment, follow-up and partners' medical care (31) . The systematic genotyping of rectal specimen positive for C. trachomatis proved useful at identifying asymptomatic patients. An analysis of the cost effectiveness of such a strategy would inform future public health actions.
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